Alan Fuhrman's most recent trade in SpringWorks Therapeutics Inc was a trade of 29,983 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on July 1, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| SpringWorks Therapeutics Inc | Fuhrman Alan | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 01 Jul 2025 | 29,983 | 0 | - | - | Stock Option (Right to Buy) | |
| SpringWorks Therapeutics Inc | Alan Fuhrman | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 01 Jul 2025 | 24,727 | 0 (0%) | 0% | - | Common Stock | |
| SpringWorks Therapeutics Inc | Fuhrman Alan | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 01 Jul 2025 | 15,318 | 0 | - | - | Stock Option (Right to Buy) | |
| SpringWorks Therapeutics Inc | Alan Fuhrman | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 01 Jul 2025 | 13,774 | 0 | - | - | Stock Option (Right to Buy) | |
| SpringWorks Therapeutics Inc | Alan Fuhrman | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 01 Jul 2025 | 12,216 | 0 | - | - | Stock Option (Right to Buy) | |
| SpringWorks Therapeutics Inc | Fuhrman Alan | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 01 Jul 2025 | 7,464 | 0 | - | - | Stock Option (Right to Buy) | |
| SpringWorks Therapeutics Inc | Alan Fuhrman | Director | 14 May 2025 | 10,060 | 24,727 (0%) | 0% | 0 | Common Stock | ||
| Tyra Biosciences Inc | Alan Fuhrman | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 9.77 per share. | 14 Mar 2025 | 1,238 | 14,087 | - | 9.8 | 12,101 | Common Stock |
| Tyra Biosciences Inc | Alan Fuhrman | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 16.00 per share. | 30 Oct 2024 | 9,500 | 12,849 | - | 16.0 | 151,954 | Common Stock |
| Tyra Biosciences Inc | Alan Fuhrman | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 12.48 per share. | 13 Sep 2024 | 954 | 3,349 | - | 12.5 | 11,904 | Common Stock |
| Tyra Biosciences Inc | Alan Fuhrman | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Aug 2024 | 115,000 | 115,000 | - | - | Stock Option (Right to Buy) | |
| Esperion Therapeutics Inc. | Alan Fuhrman | Director | 23 May 2024 | 32,500 | 32,500 | - | - | Stock Option (right to buy) | ||
| Esperion Therapeutics Inc. | Alan Fuhrman | Director | 23 May 2024 | 23,000 | 53,404 (0%) | 0% | 0 | Common Stock | ||
| SpringWorks Therapeutics Inc | Alan Fuhrman | Director | 16 May 2024 | 12,216 | 12,216 | - | - | Stock Option (Right to Buy) | ||
| SpringWorks Therapeutics Inc | Alan Fuhrman | Director | 16 May 2024 | 4,095 | 14,667 (0%) | 0% | 0 | Common Stock | ||
| Tyra Biosciences Inc | Alan Fuhrman | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 12.48 per share. | 15 Mar 2024 | 932 | 2,395 | - | 12.5 | 11,629 | Common Stock |
| Tyra Biosciences Inc | Alan Fuhrman | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Jul 2023 | 62,685 | 62,685 | - | - | Stock Option (Right to Buy) | |
| Esperion Therapeutics Inc. | Alan Fuhrman | Director | 15 Jun 2023 | 21,000 | 21,000 | - | - | Stock Option (right to buy) | ||
| Esperion Therapeutics Inc. | Alan Fuhrman | Director | 15 Jun 2023 | 5,150 | 30,404 (0%) | 0% | 0 | Common Stock | ||
| SpringWorks Therapeutics Inc | Alan Fuhrman | Director | 24 May 2023 | 13,774 | 13,774 | - | - | Stock Option (Right to Buy) | ||
| SpringWorks Therapeutics Inc | Alan Fuhrman | Director | 24 May 2023 | 4,648 | 10,572 (0%) | 0% | 0 | Common Stock | ||
| Tyra Biosciences Inc | Alan Fuhrman | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jan 2023 | 328,000 | 328,000 | - | - | Stock Option (Right to Buy) | |
| Tyra Biosciences Inc | Alan Fuhrman | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jan 2023 | 32,800 | 32,800 | - | - | Stock Option (Right to Buy) | |
| Esperion Therapeutics Inc. | Alan Fuhrman | Director | 26 May 2022 | 20,000 | 20,000 | - | - | Stock Option (right to buy) | ||
| SpringWorks Therapeutics Inc | Alan Fuhrman | Director | 19 May 2022 | 15,318 | 15,318 | - | - | Stock Option (Right to Buy) | ||
| SpringWorks Therapeutics Inc | Alan Fuhrman | Director | 19 May 2022 | 4,818 | 5,924 (0%) | 0% | 0 | Common Stock | ||
| Esperion Therapeutics Inc. | Alan Fuhrman | Director | 27 May 2021 | 12,376 | 25,254 (0%) | 0% | 0 | Common Stock | ||
| SpringWorks Therapeutics Inc | Alan Fuhrman | Director | 20 May 2021 | 6,998 | 6,998 | - | - | Stock Option (Right to Buy) | ||
| SpringWorks Therapeutics Inc | Alan Fuhrman | Director | 20 May 2021 | 1,106 | 25,227 (0%) | 0% | 0 | Common Stock |